DMAC DiaMedica Therapeutics Inc.

NASDAQ
$7.94

DiaMedica Therapeutics Inc. (DMAC) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.20 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +19.0% since its last earnings release on August 10, 2026.

DiaMedica Therapeutics Reported In-line with Estimates
Monday, August 10, 2026 · 4:30 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 4:30 PM ET
Earnings Whisper
-
vs ($0.20)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $6.88

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.